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ABSTRACT
Background: Against a background of failure to
prevent neonatal invasive early-onset group B
Streptococcus infections (GBS) in our maternity unit
using risk-based approach for intrapartum antibiotic
prophylaxis, we introduced an antenatal GBS carriage
screening programme to identify additional women to
target for prophylaxis.
Objectives: To describe the implementation and
outcome of an antepartum screening programme for
prevention of invasive early-onset GBS infection in a
UK maternity unit.
Design: Observational study of outcome of screening
programme (intervention) with comparison to historical
controls (preintervention).
Setting: Hospital and community-based maternity
services provided by Northwick Park and Central
Middlesex Hospitals in North West London.
Participants: Women who gave birth between March
2014 and December 2015 at Northwick Park Hospital.
Methods: Women were screened for GBS at 35–
37 weeks and carriers offered intrapartum antibiotic
prophylaxis. Screening programme was first introduced
in hospital (March 2014) and then in community
(August 2014). Compliance was audited by review of
randomly selected case records. Invasive early-onset
GBS infections were defined through GBS being
cultured from neonatal blood, cerebrospinal fluid or
sterile fluids within 0–6 days of birth.
Main outcome: Incidence of early-onset GBS infections.
Results: 6309 (69%) of the 9098 eligible women were
tested. Screening rate improved progressively from 42%
in 2014 to 75% in 2015. Audit showed that 98% of
women accepted the offer of screening. Recto-vaginal
GBS carriage rate was 29.4% (1822/6193). All strains
were susceptible to penicillin but 11.3% (206/1822)
were resistant to clindamycin. Early onset GBS rate fell
from 0.99/1000 live births (25/25276) in the
prescreening period to 0.33/1000 in the screening
period (Rate Ratio=0.33; p=0.08). In the subset of
mothers actually screened, the rate was 0.16/1000 live
births (1/6309), (Rate Ratio=0.16; p<0.05).
Conclusions: Our findings confirm that an antenatal
screening programme for prevention of early-onset GBS
infection can be implemented in a UK maternity setting
and is associated with a fall in infection rates.
INTRODUCTION
Group B Streptococcus (GBS) is a commensal
in the human gastrointestinal and genital
tract. It is estimated that 15–30% of pregnant
women are colonised with GBS. A third to
half of the babies born to these women will
also be colonised with GBS, and 2–3% of
those colonised will develop invasive GBS
infection such as pneumonia, septicaemia or
meningitis. Two-thirds of invasive infections
in infants occur in the ﬁrst seven postnatal
days (invasive early-onset GBS infections
(EOGBS)) and most of the remainder
present 7–90 days after birth (invasive
late-onset GBS infections (LOGBS)).1 GBS
infection is the commonest cause of neonatal
sepsis and meningitis in the western world
including the UK. In the UK, rates of inva-
sive infant GBS disease have risen signiﬁ-
cantly over the past 20 years. A recent (2014–
2015) enhanced surveillance has reported
rates of 0.54 and 0.36 per 1000 live births for
EOGBS and LOGBS infections, respectively.
These increases have occurred despite the
Strengths and limitations of this study
▪ This is the first comprehensive report in the UK
describing the successful implementation of a
group B Streptococcus infections (GBS) screen-
ing programme and its impact on reducing
early-onset GBS disease.
▪ As our results are based on an observational
rather than experimental study design, our find-
ings could be explained by factors other than the
screening programme.
▪ As a single centre study, our findings may not
be generalisable to other units.
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introduction of national guidelines in 2003 recommend-
ing a risk-based prevention approach for offering intra-
partum antibiotic prophylaxis (IAP).2–4
All current strategies for prevention of EOGBS infections
are based on the use IAP, which is known to reduce
EOGBS infection by 70–90%.5 6 According to the risk-
based prevention approach for offering IAP advocated by
the UK National Screening Committee and the Royal
College of Obstetricians and Gynaecology (RCOG),
mothers with a history of a previous baby with GBS infec-
tion, urinary infection with GBS during the index preg-
nancy or fever during labour are given intrapartum
penicillin (or clindamycin/vancomycin in women with
penicillin allergy).2 5–7 However, around 50% of mothers
of babies who develop EOGBS infection do not have risk
factors limiting the potential impact of this approach.8 In a
recent study in Northern Ireland, only 42% of women with
identiﬁable risk factors received IAP and adherence to the
guidelines was only 50–70%. Only 55.8% of neonates with
conﬁrmed EOGBS had maternal risk factors and only
25.5% of mothers of neonates with EOGBS received IAP.9
In Western Europe, the only countries other than the UK
to use a risk-based approach are the Netherlands and
Belgium. In the UK and the Netherlands, there has been a
steady increase in EOGBS rates despite more than a
decade of risk-based prevention approach for offering
IAP.2 10 In contrast, signiﬁcant reductions in EOGBS infec-
tions have been reported in countries such as the USA,
Canada, Australia, Germany and Spain, all of whom have
adopted antenatal screening programme followed by IAP
to GBS carriers to prevent EOGBS.11–14 15 As such, the best
approach to reduce EOGBS infections remains
controversial.
Geographical variation in rates of invasive GBS disease
have been noted within the UK, with North West
London identiﬁed as an area of high incidence.16
Our North West London Hospital serves an ethnically
diverse community of 500 000 people. Despite using the
nationally recommended risk-based prevention approach,
EOGBS rates in our hospital remained consistently high
since 2008, approaching four times the national rate by
2013. A consensus decision was reached among the neona-
tologists, obstetricians, midwives and microbiologists in
our hospital to introduce antenatal screening for GBS fol-
lowed by IAP to GBS carriers in 2014.
In this paper, we report the implementation of our
programme for antenatal screening for GBS followed by
IAP and subsequent changes observed in EOGBS infec-
tion rate.
METHODS
Study design
A non-randomised observation study with comparison to
historical controls.
Between March 2014 and December 2015, a programme
of antenatal screening for GBS followed by IAP for the pre-
vention of invasive EOGBS infection was implemented in
the maternity units at the Northwick Park Hospital and
Central Middlesex Hospitals, London. In the ﬁrst
6 months, this was implemented in antenatal clinics at the
Northwick Park and Central Middlesex hospitals and then
extended to community antenatal clinics in September
2014. Nearly all births took place in the maternity unit at
Northwick Park Hospital and were the only ones included
in this study. Less than 1% of women opted for home birth
or delivered in other maternity units. Local guidelines for
screening and antibiotic prophylaxis for mothers and
babies were drafted (ﬁgure 1) based on the universal
screening guidelines for prevention of early-onset GBS
infection developed by the Centers for Disease Control
and Prevention, Atlanta (2010).17
Women with no record of screening or who declined
screening were managed according to risk-based preven-
tion approach for offering IAP.
Screening
We offered pregnant women informed choice of ante-
natal GBS screening and IAP if found to be carriers.
We printed information leaﬂets about GBS in eight
languages (English, Gujarati, Arabic, Somali, Urdu,
Tamil, Polish and Rumanian). Mothers were given these
leaﬂets at their ﬁrst attendance (usually before 20 weeks
gestation) and again at 35–37 weeks’ gestation, when the
screening was performed. Using illustrated instructions
provided, most expectant mothers were able to collect
low vaginal and anorectal swabs themselves (self-
collection). Midwifery assistance was available for those
women who did not wish to collect the swabs
themselves.
Microbiology
Two swabs, one each from low vagina and anorectum
were inoculated in LIM enrichment broth (Thermo
Scientiﬁc), incubated at 35–37°C in air for 18–24 hours
and subcultured on GBS chromogenic agar medium
(Thermo Scientiﬁc Brilliance GBS Agar) and incubated
again at 35–37°C in 5% CO2 for 18–24 hours. Pink
colonies of presumed GBS were conﬁrmed by latex
agglutination tests to determine their Lanceﬁeld group-
ing. Antibiotic susceptibility tests to penicillin, clarithro-
mycin, clindamycin, vancomycin and teicoplanin were
performed using disk diffusion tests as recommended
by the British Society of Antimicrobial Chemotherapy.
(V.12 January 2013).
Neonates were considered to have invasive EOGBS
infection if GBS was cultured from their blood, cerebro-
spinal ﬂuid or other sterile ﬂuids within 0–6 days of
birth.
Audits of implementation of guidelines
Using a random number generator, we selected a
random 1% (52) sample of maternity records for vertical
audit during the period August 2014 to July 2015 to
review compliance with the screening and administra-
tion of IAP. Similarly, we conducted a horizontal audit of
a 5% (57) random sample of GBS carriers in the period
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1 March 2014 to 31 May 2015 to review whether IAP had
been administered according to our guidelines.
Data collection and analysis
Laboratory-related information was collected from the
Laboratory Information System (WinPath, Clinisys, UK)
and information regarding the mothers and birth was
collected from the hospital’s computerised maternity
information database. (Circonia Maternity Information
System, UK).
As our intervention was a service improvement initia-
tive rather than a research study, we did not perform a
statistical sample size calculation to determine the
number of the mothers who needed to be screened to
demonstrate a statistical difference in invasive
EOGBS rates. Rather all women (total population)
during the intervention period were aimed to be
included.
The key outcome measure was the incidence of
EOGBS infection per 1000 live births in babies born in
2014 and 2015 compared with the incidence in the
period 2009–2013. Binomial exact CIs were calculated
for carriage rates and the occurrence of invasive EOGBS
was compared between the two time periods using
Fisher’s Exact Test. The difference in occurrence rate
between the two groups was also expressed as a risk ratio
(ratio of the risk of EOGBS in the two groups), along
with corresponding CIs. Signiﬁcance was set at p<0.05.
We calculated the number of women needed to
screen to prevent one case of invasive EOGBS.
RESULTS
In the screening period, there were 9098 live births. The
demographics of the mothers during the screening
period, compared with those of mothers in the period
2009–2013 are shown in table 1.
The results suggested no signiﬁcant difference
between the two time periods for gestational age.
Mothers were signiﬁcantly older during screening
period, but the mean difference in age was only
0.7 years. There was a small increase (1.3%) in birth by
caesarean section in the screening period. The latter
time period saw an increase in the percentage of white
other mothers (increase from 19.9% to 26.6%) and a
reduction in black mothers (13.6% down to 9.6%).
In the 22-month period between March 2014 and
December 2015 (period when screening programme
was introduced), 6309 (69%) of the 9098 eligible
women were screened. GBS screening rate improved
progressively from 42% in 2014 to 75% in 2015 as the
programme was rolled out from the hospital-based ante-
natal clinics to the community-based clinics.
The monthly screening rates are shown in ﬁgure 2.
In the screened women, 97.8% (6193/6309) had
lower vaginal and anorectal swabs. However, the correct
Figure 1 Local guidelines for prevention of early-onset neonatal group B Streptococcus infections (GBS) disease.
Gopal Rao G, et al. BMJ Open 2017;7:e014634. doi:10.1136/bmjopen-2016-014634 3
Open Access
 o
n
 30 July 2018 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2016-014634 on 18 April 2017. Downloaded from 
timing of collection (from 35 weeks to 2 days before
birth) was only achieved in 4937/6309 women (78%).
The detected GBS carriage rate in women screened
using recto-vaginal swabs was 29.4% (1822/6193; 95% CI
28.3% to 30.6%) dropping to 20% (p<0.05) when
vaginal swabs alone (20/100; 95% CI 12% to 30%) were
collected. When rectal swabs alone were collected, 4/16
(25%) women were detected as carriers (95% CI 7.9%
to 60.3%). All strains of GBS detected in the screening
programme were sensitive to penicillin but 206/1822
(11.3%) of the isolates were resistant to clindamycin.
The vertical audit showed that 40/52 women (77%)
were offered information about GBS screening before
28 weeks gestation. Four out of 52 women gave birth
before 37 weeks. Of the remaining 48 women, 35 (73%)
were offered GBS screening at 35–37 weeks gestation.
Overall, 41/48 (85%) women were offered GBS screen-
ing at some point during their pregnancy from 35 weeks
to time of birth. Forty of the 41 (98%) accepted the
offer of GBS screening and all of the women who were
found to be GBS carriers agreed to have IAP. Eleven of
the 13 GBS positive women received IAP according to
the guidelines. The reasons why two women did not
receive IAP were not apparent from the notes.
Intrapartum antibiotic prophylaxis (IAP)
The horizontal audit of women who were GBS carriers
showed that 46 of 57 women (80.7%) were given IAP. Of
the 46 women, 42 women were given IAP at the correct
time. Four of the 46 women were not given IAP as it was
not necessary because they had elective caesarean
section without rupture of membranes. Of the 11/57
women who were not given IAP, there was insufﬁcient
time to administer IAP due to precipitate birth (within
2 hours) in six women. In another two women screening
results were not available as samples were taken immedi-
ately prior to birth. It was not clear why IAP was not pre-
scribed in two women, and in one woman IAP was
prescribed but not given.
Of the 42 women who received IAP, 35 women
(83.3%) received IAP 2 or more hours prior to birth
and 26 women (61.9%) received two or more doses of
antibiotics indicating that they had IAP at least 4 hours
before birth. The median number of doses of antibiotic
administered was 2 (range 1–7, average 2.4). All eligible
women received penicillin as none were allergic to
penicillin.
Outcomes
Three babies developed EOGBS infection during the
screening period. Of these three cases, only one was
born to a woman who had been screened. She had been
screened at 33 weeks and was negative for GBS at that
time. It is not clear why she was screened at 33 weeks.
The mother had a spontaneous vaginal delivery at term
(40 weeks). However, subsequently GBS was isolated
from a vaginal swab taken postpartum for investigation
of unexplained tachycardia in the mother.
In the period 2009–2013 when risk-based strategy was
used, 25 babies born to 25 276 mothers developed
EOGBS infection, a rate of 0.99/1000 live births. In the
period, March 2014 and December 2015, 3/9098 of all
live births and only 1/6309 babies of screened mothers
developed EOGBS infection. Annual rates of early-onset
GBS infection in the control and screening periods are
shown in ﬁgure 3.
The rate of EOGBS in babies born in the screening
period (0.33/1000 live births; 95% CI 0.09 to 0.96) was
threefold lower (Rate Ratio=0.33; 95% CI 0.10 to 1.10)
than in those born in the prescreening period 2009–
2013 (0.99/1000 live births; 95% CI 0.64 to 1.46),
although this difference did not reach statistical signiﬁ-
cance (p=0.08).
Comparing EOGBS rates in babies born to mothers
who were actually screened (0.16/1000 LB (1/6309;
95% CI 0.00 to 0.88), the rate of EOGBS was more than
ﬁve times lower (Risk Ratio=0.16 (95% CI 0.02 to 1.18;
p<0.05) compared with the prescreening period (0.99/
1000 LB (25/25 276; 95% CI 0.64 to 1.46).
Based on reductions observed in this study, the
number needed to screen to prevent one EOGBS infec-
tion was 1459 (95% CI 831 to 5984).
Table 1 Comparison of characteristics of mothers in the prescreeeningand postscreening periods
Variable Category 2009–2013 (n=25 073) 2014–2015 (n=9104)* p Value
Gestation (weeks) – 39.1±2.1 39.1±2.0 0.43
Age (years) – 29.0±5.4 29.7±5.3 <0.001
Mode of birth Caesarean 7163 (28.6%) 2698 (29.9%) 0.05
Instrumental 3162 (12.6%) 1123 (12.5%)
SVD 14 748 (58.8%) 5193 (57.6%)
Ethnicity Black 3401 (13.6%) 867 (9.6%) <0.001
British/Irish 2665 (10.7%) 770 (8.6%)
White other 4964 (19.9%) 2393 (26.6%)
Indian subcontinent 11 811 (47.2%) 4237 (47.0%)
Other 2166 (8.7%) 741 (8.2%)
Figures are Mean±SD or number (percentage).
*Complete missing demographic data in 84 mothers.
SVD, spontaneous vaginal delivery.
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DISCUSSION
Our rationale for introducing antenatal screening-based
IAP was the consistently high rate of invasive EOGBS
infection in our unit despite implementation of national
guidance which recommends risk-based IAP. A recent
national audit by the RCOG observed variable practice
in adherence to the national guidelines.18
We implemented the antenatal screening programme
because the efﬁcacy of screening-based IAP has been
established in many other countries.
A survey of the women participating in the pro-
gramme demonstrated a high level of acceptance
of screening and self-collection of the screening swabs.19
A previous study demonstrated that self-collection swabs
were as sensitive for detection of GBS as physician col-
lected swabs.20
GBS screening rate improved progressively from 42%
in 2014 to 75% in 2015 as the programme was rolled out
from the hospital-based antenatal clinics to the
community-based clinics. As the earliest opportunity for
screening was at 35–37 weeks gestation, mothers of
babies born prematurely were not screened but
managed according to the risk-based approach.
Where only vaginal swabs were collected, the GBS car-
riage rate was 20% compared with 29.4% where low
vaginal and anorectal swabs were collected. Our results
conﬁrm that low vaginal and anorectal swabs are neces-
sary to provide an accurate assessment of GBS colonisa-
tion status.21 Of women who were screened, 78% were
screened at the right time and using the right speci-
mens. The reasons for failure to screen according to our
guidelines are not clear but could be due to lack of
familiarity with the guidelines or the mothers were regis-
tered for the ﬁrst time just before birth.
The recto-vaginal GBS carriage rate in our women was
29.4%. This rate is similar to the 28% carriage rate
reported in a previous study in London and higher than
the 21% carriage rate reported in Oxford.22 23 It is likely
that the different carriage rates are due to the different
ethnic origin of the women who were screened.24 In the
Oxford study, 90% of the women described themselves as
white British. In contrast, <10% of the women screened
in our study were white British. (table 1). We observed a
signiﬁcant increase in the ‘white other’ ethnic group in
the study period compared with 2009–2013 but no signiﬁ-
cant change in other ethnic groups. A majority of
mothers in the ‘other white’ category was from Rumania,
Poland and other Eastern European countries. There was
a small increase (1.35%) in the caesarean sections in the
screening period. The reasons for this increase were not
clear. We believe that this increase is unlikely to have
affected the early-onset GBS rates.
Development of resistance is a major concern when-
ever antibiotics are administered. In our study, none of
the GBS strains were resistant to penicillin. Reassuringly,
in the US where there is widespread use of penicillin for
IAP for prevention of EOGBS, GBS continues to be sus-
ceptible to penicillin although there are reports of toler-
ance.17 25 Clindamycin is recommended as the
Figure 2 Monthly screening rates for group B Streptococcus infections (GBS).
Figure 3 Annual rates of early-onset group B Streptococcus
infections (GBS) infection in the prescreening (2009–2013)
and postscreening periods (2014, 2015).
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alternative antibiotic for IAP in women who are allergic
to penicillin. In our study population, clindamycin resist-
ance rate in GBS isolates detected by screening was
11.3%, lower than the 18% resistance in GBS bacter-
aemia isolates reported recently in the UK.26
In the absence of electronic patient records and
because screening was introduced as a service improve-
ment, we used audit methodology to evaluate compli-
ance with the guidelines rather than reviewing every
individual woman. The ‘vertical’ audit demonstrated
that 73% of the women were screened at the recom-
mended 35–37 weeks of gestation, although 85% were
screened at some time during pregnancy. The reasons
why some of the women were not screened at 35–
37 weeks are not clear. Given that only one woman
declined screening, failure to screen other women
could be due to an initial lack of awareness about ante-
natal screening programme for prevention of invasive
early-onset GBS infection and the recommended
timing for screening. The vertical audit demonstrated
overall compliance with the administration of IAP. The
horizontal audit showed a high level of compliance
with choice, dose and timing of administration of the
IAP. In 10% of women IAP could not be administered
because of precipitate labour. Overall, 83.5% of the
GBS carriers received IAP >2 hours before birth and
61.9% received IAP at least 4 hours before birth. IAP is
considered to be most effective when given 4 hours
before birth and ineffective if given <2 hours before
birth.27
Anaphylaxis or other severe allergic reactions follow-
ing administration of penicillin is understandably a
concern. None of the women included in our audits
gave history or developed allergic reactions to penicillin.
Furthermore, we are not aware of any women develop-
ing adverse reactions to IAP through our hospital’s
adverse event reporting system (Datix) or through
departmental reporting systems. In the USA, despite
administration of penicillin to millions of mothers as
IAP since 1996, there have been only four published
reports of anaphylaxis associated with GBS chemo-
prophylaxis, all non-fatal.17
We observed non-signiﬁcant reduction (p=0.08) in the
EOGBS rates in the babies born to all women in 2014
and 2015 when screening-based IAP was introduced
compared with the previous period 2009–2013. However,
there was signiﬁcant reduction in the EOGBS rate in the
screened women compared with women not screened in
the period 2009–2013. Among the screened population,
one baby with EOGBS infection was born to a mother
who was negative for GBS colonisation when she was
screened at 33 weeks. The mother was later found to be
colonised with GBS when a vaginal swab was tested as a
part of investigation for unexplained tachycardia. It is
recognised that screening swabs taken before 6 weeks of
birth fail to accurately predict GBS carriage at birth
in >50% of women.28 Following the introduction of
screening-based IAP, the EOGBS rate our maternity
service fell to a lower rate than 0.42/1000 live births
reported by the Public Health England in 2014.26
In this study, the number of women needed to screen
to prevent one case of invasive EOGBS infection was
1459 (95% CI 831 to 5984). This was considerably lower
than the 5704 cited by Angstetra et al29 in Australia.
Limitations
As our results are based on an observational rather than
experimental study design, our ﬁndings could be
explained by factors other than the screening pro-
gramme. In particular, changes in the characteristics of
patients in the two time periods may have inﬂuenced
the change in rate of infection. There was a signiﬁcant
increase in the proportion of women of ‘other white’
ethnicity was observed in 2014 and 2015 but we are
unaware of any published reports suggesting women
from these primarily Eastern and Central European
countries have a lower rate of early-onset disease.
Furthermore, as a single centre study, our ﬁndings may
not be generalisable to other units.
We did not review every individual woman’s maternity
case notes to record if adequate IAP had been given to
GBS carriers or to those with risk factors. Instead we
relied on audits of a random sample. It is possible that
the audits do not give a true picture of IAP in all
women. As a result, we cannot draw any deﬁnite conclu-
sions regarding the causal relationship between IAP
administration in screened women and the EOGBS
rates. We did not review individual case notes to identify
women who may have developed adverse reactions to
IAP. Instead, we relied on the adverse event reporting
system in the hospital. It is possible that minor adverse
events may not have been reported.
CONCLUSION
The ﬁndings of our programme conﬁrm that screening-
based intrapartum prophylaxis can be implemented and
is widely accepted by pregnant women in our maternity
unit. The programme was associated with a reduction in
invasive EOGBS infections in neonates While the reduc-
tion did not reach statistical signiﬁcance, our results
provide further evidence that screening-based intrapar-
tum prophylaxis should be considered in maternity units
in the UK where rates of EOGBS infections remain high
despite implementation of a risk-based approach.
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